Fair Value Distribution — percentile bands
56.4% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
12.6%/yr
±5.4% · revenue growth to justify current price
FCF-Based Reverse DCF
13.7%/yr
±3.4% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Boston Scientific delivered exceptional FY2025 results — .1B revenue (+19.9% reported, +15.8% organic), driven overwhelmingly by FARAPULSE PFA System dominating the atrial fibrillation EP market. Adju...